Orchard Therapeutics plc

NasdaqCM:ORTX 주식 보고서

시가총액: US$380.1m

Orchard Therapeutics 관리

관리 기준 확인 4/4

Orchard Therapeutics CEO는 Bobby Gaspar, Mar2020 에 임명되었습니다 의 임기는 3.83 년입니다. 총 연간 보상은 $ 1.45M, 39.6% 로 구성됩니다. 39.6% 급여 및 60.4% 보너스(회사 주식 및 옵션 포함). 는 $ 611.47K 가치에 해당하는 회사 주식의 0.16% 직접 소유합니다. 611.47K. 경영진과 이사회의 평균 재임 기간은 각각 2.7 년과 5.6 년입니다.

주요 정보

Bobby Gaspar

최고 경영자

US$1.4m

총 보상

CEO 급여 비율39.6%
CEO 임기3.8yrs
CEO 소유권0.2%
경영진 평균 재임 기간2.7yrs
이사회 평균 재임 기간5.6yrs

최근 관리 업데이트

Recent updates

Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR

Jan 19

Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

May 09
Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price

Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Mar 10
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?

Orchard Therapeutics: Gene Therapy For Rare Child Disease

Aug 19

Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M

Aug 04

Orchard Therapeutics: Shadow Of Former Glory

Jan 20

Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles

Aug 16

Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

Jun 14
Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?

What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Feb 03
What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?

Orchard Therapeutics appoints Braden Parker as chief commercial officer

Jan 29

Orchard Therapeutics' OTL-200 wins FDA's RMAT status

Jan 14

Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022

Jan 12

Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Jan 08
Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?

Orchard Therapeutics' MLD gene therapy wins European nod

Dec 21

Our View On Orchard Therapeutics

Dec 17

Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Dec 11
Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year

Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study

Dec 08

Orchard Therapeutics (ORTX) Investor Presentation - Slideshow

Nov 22

CEO 보상 분석

Bobby Gaspar 의 보수는 Orchard Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2023n/an/a

-US$73m

Jun 30 2023n/an/a

-US$85m

Mar 31 2023n/an/a

-US$124m

Dec 31 2022US$1mUS$573k

-US$151m

Sep 30 2022n/an/a

-US$179m

Jun 30 2022n/an/a

-US$168m

Mar 31 2022n/an/a

-US$154m

Dec 31 2021US$4mUS$605k

-US$145m

Sep 30 2021n/an/a

-US$142m

Jun 30 2021n/an/a

-US$126m

Mar 31 2021n/an/a

-US$137m

Dec 31 2020US$4mUS$543k

-US$152m

Sep 30 2020n/an/a

-US$164m

Jun 30 2020n/an/a

-US$180m

Mar 31 2020n/an/a

-US$183m

Dec 31 2019US$921kUS$344k

-US$163m

Sep 30 2019n/an/a

-US$143m

Jun 30 2019n/an/a

-US$140m

Mar 31 2019n/an/a

-US$246m

Dec 31 2018US$2mUS$338k

-US$230m

보상 대 시장: Bobby 의 총 보상 ($USD 1.45M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 2.18M ).

보상과 수익: Bobby 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Bobby Gaspar (60 yo)

3.8yrs

테뉴어

US$1,447,526

보상

Dr. Hubert Baburaj Gaspar, M.D. Ph.D. also known as Bobby, has been Chief Executive Officer at Orchard Therapeutics plc (Formerly known as Orchard Therapeutics Limited) since March 18, 2020. He serves as a...

리더십 팀

이름위치테뉴어보상소유권
Hubert Gaspar
CEO, Member of Scientific Advisory Board & Executive Director3.8yrsUS$1.45m0.16%
$ 611.5k
Frank Thomas
President & COO4yrsUS$1.21m0.040%
$ 153.8k
Nicoletta Loggia
Chief Technical Officer2.3yrs데이터 없음데이터 없음
Fulvio Mavilio
Chief Scientific Officer2yrs데이터 없음데이터 없음
Renee Leck
Head of Investor Relationsno data데이터 없음데이터 없음
Benjamin Navon
Director of Corporate Communicationsno data데이터 없음데이터 없음
John Cerio
Chief Human Resource Officerno data데이터 없음데이터 없음
Robin Kenselaar
Senior VP & GM of EMEA Commercial Operations5.2yrs데이터 없음데이터 없음
Braden Parker
Chief Commercial Officer3yrs데이터 없음데이터 없음
Leslie Meltzer
Chief Medical Officer2.3yrs데이터 없음데이터 없음
Christopher York
Company Secretary1.9yrs데이터 없음데이터 없음

2.7yrs

평균 재임 기간

경험이 풍부한 관리: ORTX 의 관리팀은 경험 ( 2.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Hubert Gaspar
CEO, Member of Scientific Advisory Board & Executive Director7.9yrsUS$1.45m0.16%
$ 611.5k
James Arthur Geraghty
Independent Chairman5.7yrsUS$107.72k0.019%
$ 74.1k
Marc Dunoyer
Independent Non-Executive Director5.6yrsUS$71.72k0.016%
$ 62.1k
Charles Rowland
Independent Non-Executive Director5.5yrsUS$90.72k0.0054%
$ 20.5k
Donald Kohn
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Alessandra Biffi
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Brian Bigger
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Simon Jones
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Adrian Thrasher
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
David Williams
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Robert Wynn
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Harry Malech
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

5.6yrs

평균 재임 기간

67yo

평균 연령

경험이 풍부한 이사회: ORTX 의 이사회는 경험(평균 재직 기간 5.6 년)으로 간주됩니다.